Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign

被引:1
|
作者
Gbenewei, Ene [1 ]
Nomhwange, Terna [2 ]
Taiwo, Lydia [3 ]
Ayodeji, Isiaka [2 ]
Yusuf, Kabir [1 ]
Baptiste, Anne E. Jean [2 ]
Nsubuga, Peter [4 ]
Braka, Fiona [2 ]
Oteri, Joseph [1 ]
Shuaib, Faisal [1 ]
机构
[1] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria
[2] WHO Country Off Nigeria, Abuja, Nigeria
[3] AFENET Country Off Nigeria, Abuja, Nigeria
[4] Global Hlth Solut, Atlanta, GA USA
关键词
AEFI (Adverse Event following Immunization); Measles; Supplemental immunization activities; Nigeria;
D O I
10.1016/j.vaccine.2021.02.067
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: An Adverse event following immunization (AEFI) is an untoward medical occurrence following immunization and which may not have a necessary causal relationship with the usage of a vaccine. The World Health Organization categories AEFI into two; serious and non-serious. An AEFI is considered serious if it is life-threatening, requires inpatient hospitalization or results in death. The measles vaccine is safe and effective however because it is a live-attenuated injectable vaccine it is more prone to AEFI as compared to non-injectable vaccines when given in large numbers over a short period as is the nature of measles mass vaccination campaigns (MVC). This article describes Nigeria's experience on AEFI reporting during the 2017/2018 Measles vaccination campaign (MVC). Methods: We reviewed various materials which included the Open Data Kit (ODK) which is an open source smartphone-based data collecting tool, operations room reports, measles campaign tally sheets, AEFI line listing forms, the post measles campaign coverage survey report and the report of the AEFI national expert committee review of the 2017/2018 Nigeria measles MVC. Results: A total of 6,214 suspected cases of AEFI were line listed from all 36 states and the Federal Capital Territory(FCT) during the 2017/2018 MVC with Fever(38%) and pain at injection site the (30%)most common reports. Overall, 99.7% AEFIs were reported to be non-serious AEFIs, with almost all cases resolved fully with no long-term sequalae.. The national incidence of suspected AEFI per 100,000 population was 16.3 with subnational incidence highest in Kebbi state (101.3/100,000) and lowest in Bayelsa state (0.8/100,000). Conclusion: Adequate AEFI reporting, Investigation and management remains important in managing the risk of a disruption of mass campaigns. The deployment of supervisors during campaign may play an important role in improving the identification and reporting of suspected AEFI. Further inquiries about AEFIs during the post campaign coverage evaluation also played a role in improving AEFI reporting and documentation. The real-time, on the spot, follow up by the national operations team helped with decision making and intervention including AEFI investigations and assessments. (C) 2021 World Health Organization. Published by Elsevier Ltd.
引用
收藏
页码:C82 / C88
页数:7
相关论文
共 50 条
  • [1] Microplanning verification and 2017/2018 measles vaccination campaign in Nigeria: Lessons learnt
    Hamisu, Maimuna
    Dieng, Boubacar
    Taiwo, Lydia
    Baptiste, Anne Eudes Jean
    Bawa, Samuel
    Wagai, John
    Ibizugbe, Samuel
    Braka, Fiona
    Nsubuga, Peter
    Shuaib, Faisal
    Oteri, Joseph
    [J]. VACCINE, 2021, 39 : C46 - C53
  • [3] Planning for supplemental immunization activities using the readiness assessment dashboard: Experience from 2017/2018 Measles vaccination campaign, Nigeria
    Richard, Minkop Terna
    Taiwo, Lydia
    Baptiste, Anne Eudes Jean
    Bawa, Samuel
    Dieng, Boubacar
    Wiwa, Owens
    Lambo, Kikelomo
    Braka, Fiona
    Shuaib, Faisal
    Oteri, Joseph
    [J]. VACCINE, 2021, 39 : C21 - C28
  • [4] Using data to improve outcomes of supplemental immunisation activities: 2017/2018 Nigeria measles vaccination campaign
    Mogekwu, Fred Ikechukwu
    Oteri, Joseph A.
    Nsubuga, Peter
    Ezebilo, Obiora
    Maxwell, Nikki
    Wiwa, Owens
    Braka, Fiona
    Shuaib, Faisal
    [J]. VACCINE, 2021, 39 : C38 - C45
  • [5] Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria
    Momoh, Jenny
    Oteri, Avuwa Joseph
    Mogekwu, Fred
    Onwu, Nneka
    Dieng, Boubacar
    Bawa, Samuel
    Braka, Fiona
    Nsubuga, Peter
    Shuaib, Faisal
    [J]. VACCINE, 2021, 39 : C12 - C20
  • [6] 2017 Measles-Rubella Vaccination Campaign in India
    Shrivastava, Saurabh RamBihariLal
    Shrivastava, Prateek Saurabh
    Ramasamy, Jegadeesh
    [J]. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2018, 9
  • [7] Application of the Geographic Information System (GIS) in immunisation service delivery; its use in the 2017/2018 measles vaccination campaign in Nigeria
    Oteri, Joseph
    Hussaini, Mohammed Idi
    Bawa, Samuel
    Ibizugbe, Samuel
    Lambo, Kikelomo
    Mogekwu, Fred
    Wiwa, Owen
    Seaman, Vincent
    Kolbe-Booysen, Olivia
    Braka, Fiona
    Nsubuga, Peter
    Shuaib, Faisal
    [J]. VACCINE, 2021, 39 : C29 - C37
  • [8] Measles Resurgence Following a Nationwide Measles Vaccination Campaign in Nigeria, 2005-2008
    Weldegebriel, Goitom G.
    Gasasira, Alex
    Harvey, Pauline
    Masresha, Balcha
    Goodson, James L.
    Pate, Muhammad A.
    Abanida, Emmanuel
    Chevez, Ana
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 204 : S226 - S231
  • [9] Estimating the cost of adverse events following immunization of measles rubella vaccine in a mass vaccination campaign in Eastern Uganda
    Muhoozi, Michael
    Tusabe, Joan
    Kagaayi, Joseph
    Nyabigambo, Agnes
    Kajungu, Dan
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 675 - 675
  • [10] Adverse events associated with Measles and Rubella vaccination campaign 2019 in India
    Sharma, Roop
    Gaur, Ajay
    [J]. CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2021, 10 (01) : 44 - 46